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INTRODUCTION
Osteoporosis is defined as a skeletal disorder characterized
by compromised bone strength predisposing a person to an
increased risk of fracture (1). It has been estimated that bone
mineral density (BMD) accounts for approximately 70% of
bone strength, and that at least 70% of BMD variance is at-
tributed to genetic factors (2). A number of candidate genes
have been investigated in terms of their potential involvements
in the regulation of bone mass in various populations, but
the results have been conflicting (3 ,4) and osteoporosis genes
have not been defined yet. To date, we have demonstrated
that the estrogen receptor (ER) PvuII and XbaI polymor-
phisms (5), the insulin-like growth factor (IGF-I) (CA) poly-
morphism (6), and the vitamin D receptor (VDR) baTL hap-
lotype (7) and the osteoprotegerin (OPG) gene G1181C poly-
morphism (8), are candidate genetic factors in Korean women.
It has been suggested that bone mass may be affected by mul-
tiple genes, and therefore, further studies on other candidate
genes are required.
The Wnt/β -cateninin signaling pathway has been shown
to play a major role in the control of bone formation, and is
specifically involved in osteoblast proliferation, differentiation,
and apoptosis (9-12). In order to transduce the canonical sig-
nal, Wnts bind to two different receptors: the low density
lipoprotein receptor-related protein (LRP) 5/6 and frizzled re-
ceptor (FZD) family members. Recently it has been reported
that single nucleotide polymorphisms (SNPs) in the LRP gene
may be associated with bone mass, depending on ethnicity
(13, 14). We have recently reported non-association of LRP
SNPs with bone mass in postmenopausal Korean women (15).
There are 10 members of the FZD gene family in humans.
It has been suggested that not all FZD have the same func-
tions in the Wnt signaling pathway, indicating the existence
of inhibitory and stimulatory FZD (9). Furthermore it has
been reported that the Wnt pathway might be associated
with OPG-receptor activator of the NF-κ B (RANK) ligand
system which is known to regulate osteoclast formation and
activity (16, 17). The aim of the present study was to inves-
tigate the association between polymorphisms of the FZD
genes, and circulating OPG, soluble RANK ligand (sRAN-
KL) levels, bone turnover marker levels, and BMD in post-
menopausal Korean women.
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We investigated the association between single nucleotide polymorphisms (SNPs)
in the frizzled (FZD) genes in the Wnt signal pathway and circulating osteoprotegerin
(OPG), soluble receptor activator of NF-κ B ligand (sRANKL) levels, bone turnover
markers, and bone mineral density (BMD) in postmenopausal women. The SNPs
in the FZD1, FZD5, FZD6, FZD7, and FZD9 genes were analyzed by direct sequenc-
ing in 371 postmenopausal Korean women. Levels of serum OPG, sRANKL, osteo-
calcin, C-telopeptide of type I collagen, calcium, parathyroid hormone and calcitonin,
and BMD at the lumbar spine and femoral neck were measured. The SNPs in the
FZD1, FZD5, FZD7, and FZD9 genes, and in exon 2 of the FZD6 gene were not
observed. No significant differences in the adjusted BMD of lumbar spine and femoral
neck and serum levels of OPG, sRANKL, and bone markers were noted among the
single or haplotype genotypes of the L345M and E664A SNPs in the FZD6 gene
and the distributions of these single or haplotype genotypes were not different accord-
ing to the bone mass status. In conclusion, the polymorphisms of the FZD genes
are not associated with BMD of the lumbar spine and femoral neck, bone turnover
markers, or circulating OPG-sRANKL in Korean women.
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Subjects 
The current study included 371 postmenopausal women
between the ages of 48 and 70 yr, who attended the Meno-
pause Clinic of Seoul National University Hospital for bone
mass examination and who agreed to participate. All of the
subjects had been without spontaneous menses for at least
one year, and underwent a careful physical examination, and
a medical history review. Blood glucose levels, and hepatic
and renal functions were determined in the participants. Wo-
men who had undergone bilateral oophorectomy or women
with current hepatic disease, renal disease, or diabetes mel-
litus were excluded. None of the subjects had received any
medication known to affect bone metabolism before the study.
All subjects provided their informed consent, and the study
protocol was approved by the Institutional Review Board of
Seoul National University Hospital.
Measurements of BMD and body mass index (BMI) 
The BMD was measured in grams per square centimeter
at the lumbar spine (L2-L4), femoral neck, trochanter, and
Ward’s triangle, using a Lunar DPX-L dual-energy radiog-
raphy absorptiometer (Lunar Radiation Corp., Madison, WI,
U.S.A.), and categorized into the following three groups
according to the criteria of the World Health Organization
(18) as, normal, osteopenic, or osteoporotic, relative to the
means and standard deviation of young adult Korean women.
The in vivo coefficient of variation was 1.4% for the lumbar
spine, 2.1% for the femoral neck, 1.1% for the trochanter,
and 2.1% for Ward’s triangle. The BMI was calculated by
dividing body weight (kg) by the square of body height (m
2)
Measurements of bone turnover markers 
Blood samples were collected from all of the subjects in
accordance with the guidelines of the Declaration of Helsin-
ki. Serum osteocalcin (OST) was measured using a competi-
tive radioimmunoassay kit (Techno Genetics, Milano, Italy).
The minimum detection limit was 0.6 ng/mL, and intra- and
inter-assay variations for OST were 4.0% and 5.1%, respec-
tively. Serum carboxy-terminal C-telopeptide of type I colla-
gen (CTX) was measured using a serum CrossLaps One Step
enzyme-linked immunosorbent assay kit (Osteometer Bio-
tech, Herlev, Denmark). The minimum detection limit was
94 pM/L and intra- and inter-assay variations for CTX were
5.4% and 5.1% respectively.
Measurement of serum calcitonin, parathyroid hormone
(PTH), and calcium (Ca) 
Calcitonin was measured using an immunoradiometric assay
kit (CIS bio international, Yvette Cedex, France). The mini-
mum detection limit was 1.5 pg/mL, and intra- and inter-
assay variations for calcitonin were 3.4% and 3.1%, respec-
tively. PTH was measured using a total intact PTH immuno-
radiometric assay kit (IBL, Hamburg, Germany). The mini-
mum detection limit was 1 pg/mL and inter- and intra-assay
variations for PTH were 2.7% and 3.4%, respectively. Ca was
measured by an atomic extinction photometer.
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Types of FZD dbSNP ID Locations Base changes Amino acid changes PCR primers
FZD1 rs3752146 Exon 1 A/G Met 343 Val F: GTGAGCCGACCAAGGTGTAT
R:TCATGAAGAGGATGGTGCAG
FZD5 rs1056614 Exon 2 A/T Thr 88 Ser F: CAACCAGTTCAACCACGACA
R: CGGTTGTAATCCATGCAGAG
FZD6 rs827528 Exon 2 G/A Val 33 Met F: TTGGATGGGGATCTTCTGAG
R: GCGGCAATACTCTGGCATAA
rs3808553 Exon 4 C/A Leu 345 Met F: ATAAGGCTTGCACCGTTTTG
R: AAAGGCACAGTGGCAAGAAT
rs12549394 Exon 7 A/C Glu 664 Ala F: TATTGCACTCCAGCCTAGCA
R: AACCACCTCCCTGCTCTTTT
FZD7 rs1154613 Exon 1 C/T Leu 282 Phe F: CCCCACTGCCTACCCTACC
R: ATGAAGTAGCAGCCCGACAG
FZD9 rs17852398 Exon 1 G/C Arg 199 Pro F: CCCATCATGGAGCAGTTCA
R: GAAGGCGGTGGAGAAGAAG
rs17856756 Exon 1 G/A Val 448 Ile F: CTGGTGCTGGGCAGTAGTTT
R: GCTAGAGGTGTGTGTGGGGTTC
rs17856757 Exon 1 A/G Asn 524 Ser F: same as F1
R: same as R1
rs17852397 Exon 1 A/G His 556 Arg F: same as F1
R: same as R1
Table 1. FZD family SNPs studied and their PCR primers
FZD, frizzled; SNPs, single nucleotide polymorphisms; PCR, polymerase chain reaction.Measurement of serum OPG and sRANKL
Serum OPG was measured using an enzyme-linked immu-
nosorbent assay kit (R&D, Minneapolis, MN, U.S.A.). The
minimum detection limit was 0.06 ng/mL and inter- and intra-
assay variations for OPG were 7.0% and 5.9% respectively.
Serum sRANKL was measured using an enzyme immunoas-
say kit (Biomedica Gruppe, Wien, Austria). The minimum
detection limit was 1.6 pg/mL and the inter- and intra-assay
variation for sRANKL were 7.2% and 3.9%, respectively.
Determination of the polymorphisms of the FZD genes
Genomic DNA was extracted from the peripheral blood
leukocytes using a QIAamp DNA blood kit (Qiagen GmbH,
Hilden, Germany). The polymorphic regions of the FZD genes
were amplified by polymerase chain reaction (PCR) with spe-
cific forward and reverse primers as shown in Table 1. PCR
products were electrophoresed through 1.5% agarose gel to
verify the reaction, and purified directly from PCR reaction
using a PCR clean kit (Qiagen GmbH, Hilden, Germany).
The PCR product sequences were determined by cycle sequ-
encing using an ABI PRISM Bigdye Terminator Cycle Sequ-
encing Ready Reaction kit (Applied Biosystems, Foster City,
CA, U.S.A.) on an automated DNA sequencer ABI PRISM
310 (PE Applied Biosystems). 
Statistical analyses
All data are expressed as mean±SE. All statistical analyses
were performed using the Statistical Package for Social Sci-
ence (SPSS, Chicago, IL, U.S.A.). Genotype frequencies for
each polymorphism were tested against the Hardy-Weinberg
equilibrium by the chi-square test. Linkage disequilibria re-
sulting from the non-random associations of genotypes at
polymorphic sites, were also assessed by the chi-square test.
Differences in anthropometric characteristics between the di-
fferent FZD genotypes or haplotypes were tested using the
Student’s t-test or one way analysis of variance (ANOVA),
followed by Tukey’s multiple comparison test. Similar com-
parisons were made after adjusting the BMD and the levels
of OPG, sRANKL or biochemical markers for potential con-
founding factors such as age, years since menopause, and BMI,
using analysis of covariance (ANCOVA). A Pvalue of less than
0.05 was considered to be significant for all analyses.
RESULTS
Single polymorphisms
The SNPs in the FZD1, FZD5, FZD7, and FZD9 genes,
and in exon 2 of the FZD6 gene were not observed. The dis-
tributions of the L345M SNP in the exon 4 and the E664A
SNP in the exon 8 of FZD6 gene were as follows: LL 36.4%,
LM 43.7%, MM 19.9%, AA 95.7%, and AE 4.3%. These
allele and genotype frequencies did not deviate from the
Hardy-Weinberg equilibrium. 
After adjusting for potential confounding factors, such as
age, BMI, and years since menopause, no significant differ-
ences in the BMD of the lumbar spine and proximal femur
were noted among the genotypes of the L345M and the E-
664A SNPs in FZD6 gene (Table 2). As shown in Table 3,
the prevalences of genotypes of these FZD6 polymorphisms
were not different among normal, osteopenic and osteoporot-
ic postmenopausal women.
No statistically significant differences in the adjusted serum
levels of OPG, or sRANKL, or sRANKL×1,000/OPG ratios
were found for these genotypes of the FZD6 gene polymor-
phisms (Table 4). Similar findings were obtained for the ad-
justed serum levels of bone turnover markers, such as, CTX,
OST, PTH, calcitonin, and Ca.
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P, ANCOVA; P*, Student’s t-test; 
� values, adjusted for age, years since menopause, and BMI. Values are mean±SE. 
FZD, frizzled; SNPs, single nucleotide polymorphisms; BMI, body mass index. 
Exon 4 L345M Exon 7 E664A
LL LM MM
P
AA AE
P*
(n=135) (n=162) (n=74) (n=355) (n=16)
Age (yr) 58.0±0.6 57.7±0.5 57.2±0.7 0.72 57.8±0.3 57.6±1.5 0.90
Years since menopause 9.4±0.6 9.1±0.6 9.1±0.7 0.94 9.2±0.4 9.0±1.3 0.90
Weight (kg) 58.7±0.7 57.9±0.5 58.1±0.7 0.66 58.3±0.4 57.0±1.3 0.44
Height (cm) 155.2±0.4 155.3±0.4 155.8±0.6 0.63 155.4±0.2 153.9±1.0 0.22
BMI (kg/m
2) 24.4±0.3 24.0±0.2 24.0±0.3 0.49 24.1±0.2 24.1±0.6 0.92
Bone mineral density (g/cm
2)
�
Lumbar spine 1.002±0.015 1.009±0.015 0.999±0.020 0.92 1.005±0.009 0.998±0.046 0.89
Femoral neck 0.813±0.013 0.817±0.010 0.830±0.017 0.69 0.818±0.007 0.819±0.033 0.97
Ward’s triangle 0.711±0.010 0.732±0.014 0.741±0.019 0.87 0.725±0.008 0.757±0.037 0.42
Trochanter 0.631±0.013 0.660±0.011 0.649±0.020 0.26 0.647±0.008 0.674±0.046 0.47
Table 2. Clinical characteristics and bone mineral density in postmenopausal women in relation to the FZD6 SNPsCombined polymorphisms 
Strong linkage disequilibrium was found between the
L345M and E664A polymorphisms (
2=9.032, P<0.05).
Three different haplotype alleles (ME, MA, and LA) were
identified by haplotype analysis for these two polymorphisms
of the FZD 6 gene in combination, and these haplotypes
combined to give five different genotypes: LAMA (42.0%),
LALA (35.8%), MAMA (18.1%), MELA (2.2%), and MAME
(1.9%). However, these haplotype alleles or genotypes were
found to have no significant association with the adjusted
BMDs of all skeletal sites measured, or with the serum lev-
els of OPG, RANKL, CTX, OST, PTH, calcitonin, and Ca. 
DISCUSSION
It has been demonstrated that the canonical Wnt/β -catenin
pathway modulates most aspects of osteoblast physiology,
including proliferation, differentiation, bone matrix forma-
tion and mineralization, and apoptosis. This signaling is ini-
tiated following binding of Wnt proteins to the FZD and
LRP5/6 receptors (9-12). To the best of our knowledge, this
is the first study conducted to establish an association between
bone mass and the SNPs in the FZD genes. 
We investigated non-synonymous SNPs in the FZD1,
FZD5, FZD6, FZD7, and FZD9 genes, which have been reg-
istered in the SNP database by the National Center For Bio-
technology Information (dbSNP). The SNPs in the FZD1,
FZD5, FZD7, and FZD9 genes, and in exon 2 of the FZD6
gene were not polymorphic in our study subjects. The fre-
quencies of the L allele of the L345 SNP and the E allele of
the E664A SNP in the FZD6 gene were comparable to that
reported in Asian dbSNP. 
FZD6 is located on chromosome 8q22.3 (19). It has been
reported that the FZD6 transcript is detected in calvaria and
primary osteoblast (20), and decreased in osteoblasts after
10 days of culture in conditions favoring mineralization (9).
Human FZD6 acts as a negative regulator of the canonical
Wnt/β ‚-catenin signaling cascade (21), which is believed to
play a substantial role in the control of bone formation. In
the present study, no significant association between C345A
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P, ANCOVA; P*, Student’s t-test.
Values are mean±SE. 
OPG, osteoprotegerin; RANKL, receptor activator of the NF-κ B (RANK) ligand; FZD, frizzled; SNPs, single nucleotide polymorphisms; CTX, CrossLaps;
OST, osteocalcin; PTH, parathyroid hormone; Ca, calcium. 
FZD, frizzled; SNPs, single nucleotide polymorphisms.
Exon 4 L345M Exon 7 E664A
LL LM MM
P
AA AE
P*
(n=90) (n=105) (n=41) (n=277) (n=9)
Serum OPG-sRANKL
OPG (pg/mL) 9,336.5±277.4 9,083.4±319.8 9,734.4±489.4 0.47 9,317.9±191.4 9,143.6±1,811.2 0.85
sRANKL (pg/mL) 7.4±0.7 7.7±0.7 10.6±3.3 0.30 8.3±0.8 5.6±0.2 0.46
sRANKL×1,000/OPG 0.8±0.1 1.0±0.1 1.3±0.5 0.36 1.0±0.1 0.7±0.1 0.61
Serum bone markers
CTX (pM/L) 1,438.1±152.3 2,412.6±651.0 1,296.9±299.4 0.24 1,856.7±310.7 1,605.6±515.8 0.88
OST (ng/mL) 13.6±1.0 15.0±0.6 13.6±1.2 0.25 12.1±1.1 12.1±1.1 0.32
PTH (pg/mL) 10.6±1.0 9.9±0.7 9.3±1.3 0.63 8.6±3.9 8.6±3.9 0.57
Calcitonin (pg/mL) 4.8±0.6 5.0±0.7 5.0±0.7 0.98 4.8±0.4 7.0±1.8 0.24
Ca (mg/dL) 8.9±0.1 9.1±0.1 9.3±0.1 0.07 9.4±0.2 9.4±0.2 0.23
Table 4. Serum levels of OPG, RANKL and bone turnover markers in postmenopausal women in relation to FZD6 SNPs
Polymorphic sites Genotypes
Normal Osteopenia Osteoporosis
Cross-tabulation test
(n=93) (n=175) (n=103)
Exon 4 L345M LL 30 (32.3%) 68 (38.9%) 36 (35.0%) P=0.54
LM 46 (49.5%) 71 (40.6%) 46 (44.7%) P=0.37
MM 17 (18.3%) 36 (20.6%) 21 (20.4%) P=0.90
2=2.07, P=0.72
Exon 7 E664A AA 90 (96.8%) 167 (95.4%) 98 (95.1%)
AE 31 (3.2%) 8 (4.6%) 5 (4.9%)
2=0.37, P=0.82
Table 3. Distribution of single genotype of the FZD6 SNPs according to the bone mass statusor A664C SNPs in the FZD6 gene and BMD at skeletal sites
measured or circulating levels of bone turnover markers were
noted. Haplotype analysis on the L345M and E664A SNPs
in combination showed similar findings. Our results may in-
dicate that SNPs in FZD6 gene may not be involved in the
regulation of bone mass or bone remodeling.
It has been demonstrated that the secreted antagonist of
the Wnt/β ‚-catenin signaling pathway regulates the expres-
sion of OPG- RANKL of bone tissue (16). Secreted FZD relat-
ed protein, which is highly homologous to the Wnt binding
protein of FZD and is capable of binding Wnt, has been sho-
wn to bind RANKL, resulting in inhibition of osteoclasto-
genesis (16). In this study, SNPs in FZD6 gene did not affect
circulating OPG-sRANKL levels.
The present study had several limitations. First, this study
group was composed of ethnically homogenous Korean women
and undertaken in relatively small number of women who
attended a menopause clinic. Second, limited numbers of
SNP in the FZD genes were analyzed. Therefore, further
studies including other SNPs in the FZD genes are necessary
in a larger general population and in other ethnic groups.
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